Ikonisys gets US nod to market automated prenatal diagnostic:
This article was originally published in Clinica
Executive Summary
The US FDA has given Ikonisys clearance to market its automated scanning microscope-based test for prenatal genetic diagnosis. The Ikoniscope fastFISH amnio test system is an in vitro diagnostic for aiding in the detection of the most common chromosomal aneuploidies for chromosomes 21 (Down's syndrome), 18 (Edward syndrome), 13 (Patau syndrome) and for numerical aberrations for sex chromosomes X and Y. The test can provide a result within 24-36 hours. Commenting on the US approval, Ikonisys chairman and CEO Petros Tsipouras said: "It will give us the opportunity to market our first product - to the largest market in the world."
You may also be interested in...
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.